HLB Life Science (067630) stock
KOSDAQ · Health Care Equipment & Supplies
As of the Nov 16 regular-session close (Korea)
- Market cap
- Not available
- Date not confirmed
- P/E
- Not available
- Trailing twelve months
- P/B
- Not available
- Latest reported equity
- P/S
- Not available
- Trailing twelve months
- ROE
- Not available
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
The price date behind the multiples is not confirmed; they may differ from the current price.
- Market cap
- Not available
- Date not confirmed
- P/E
- Not available
- Trailing twelve months
- P/B
- Not available
- Latest reported equity
- P/S
- Not available
- Trailing twelve months
- ROE
- Not available
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
The price date behind the multiples is not confirmed; they may differ from the current price.
Earnings
Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| Q2 2026Consolidated · Filed Aug 13, 2026 | KRW 14.7 billion | -KRW 7.6 billion | -KRW 8.7 billion | — |
| Q1 2026Consolidated · Filed May 15, 2026 | KRW 15.2 billion | -KRW 6.5 billion | -KRW 7.8 billion | -44.7% |
| Q4 2025Consolidated · Filed Mar 23, 2026 | KRW 10.9 billion | -KRW 5.8 billion | KRW 20.1 billion | — |
| 9M 2025Consolidated · Filed Nov 14, 2025 | KRW 34.8 billion | -KRW 16.2 billion | -KRW 120.1 billion | +53.2% |
| Q1 2025Consolidated · Filed May 15, 2025 | KRW 27.5 billion | -KRW 5.9 billion | -KRW 57.2 billion | +15.0% |
| Q4 2024Consolidated · Filed Mar 20, 2025 | KRW 28.7 billion | -KRW 6.8 billion | -KRW 58.6 billion | — |
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| FY2025Consolidated · Filed Mar 23, 2026 | KRW 45.8 billion | -KRW 22 billion | -KRW 99.9 billion | — |
| FY2024Consolidated · Filed Mar 20, 2025 | KRW 102.2 billion | -KRW 24.8 billion | KRW 6.2 billion | — |
- Q2 2026 is computed as H1 2026 minus Q1 2026.
- Q4 2025 is computed as FY2025 minus 9M 2025.
- Q4 2024 is computed as FY2024 minus 9M 2024.
- Year-to-date rows are cumulative from the start of the fiscal year.
Short selling and securities lending
Short sales as a share of trading value, the reported short position and the securities lending balance.
- Short-sale share
- 13.20%
- Of trading value on Nov 13, 2026
- Short-sale value
- KRW 40 million
- Previous 20-day average 13.62%
- Net short position
- 2,014,972 shares
- As of Nov 11, 2026 · reported with a two-trading-day lag
- Lending balance
- 5,193,638 shares
- As of Nov 13, 2026 · 4.26% of listed shares
| Date | Share | Value |
|---|---|---|
| Nov 13, 2026 | 13.20% | KRW 40 million |
| Nov 12, 2026 | 16.04% | KRW 60 million |
| Nov 11, 2026 | 8.91% | KRW 60 million |
| Nov 10, 2026 | 7.65% | KRW 40 million |
| Nov 9, 2026 | 5.47% | KRW 50 million |
| Nov 6, 2026 | 8.53% | KRW 50 million |
| Nov 5, 2026 | 15.88% | KRW 140 million |
| Nov 4, 2026 | 4.87% | KRW 120 million |
| Nov 3, 2026 | 23.54% | KRW 160 million |
| Nov 2, 2026 | 15.87% | KRW 200 million |
The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.
Filings
Major filings received by DART, Korea’s regulatory filing system.
- Adjustment of Exchange Price (Series 15)(Korean)Nov 13, 2026 · Conversion or Exercise Price Adjustment
- Early Acquisition of Convertible Bonds (Including Overseas) (Series 13)(Korean)Aug 31, 2026 · Bond Issuance
- Decision on Acquisition of Shares in Another Company(Korean)Aug 28, 2026 · Investment
- Decision on Disposal of Shares in Another Company(Korean)Aug 26, 2026 · Investment
- Adjustment of Exchange Price (Series 16)(Korean)Aug 20, 2026 · Conversion or Exercise Price Adjustment
- Early Acquisition of Convertible Bonds (Including Overseas) (Series 13)(Korean)Aug 14, 2026 · Bond Issuance
- Report on Major Holdings of Shares (General Form)(Korean)Jul 1, 2026 · Major Holding Report
- Report on Specified Securities Held by Executives and Major Shareholders(Korean)Jul 1, 2026 · Insider Ownership Report
Filings with a published English version open in English; the rest link to the Korean original.
HLB Life Science (067630) stock information
KOSDAQ
HLB Life Science (067630) is listed on KOSDAQ. These figures are computed in-house from official filings and are reference information only.
HLB Life Science — frequently asked questions
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.